1
|
Mariappan TT, Kurawattimath V, Gautam SS, Kulkarni CP, Kallem R, Taskar KS, Marathe PH, Mandlekar S. Estimation of the Unbound Brain Concentration of P-Glycoprotein Substrates or Nonsubstrates by a Serial Cerebrospinal Fluid Sampling Technique in Rats. Mol Pharm 2014; 11:477-85. [DOI: 10.1021/mp400436d] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T. Thanga Mariappan
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Vishwanath Kurawattimath
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Shashyendra Singh Gautam
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Chetan P. Kulkarni
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Rajareddy Kallem
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Kunal S. Taskar
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Biocon Park, Plot 2 & 3, Bommasandra IV Phase, Bangalore 560 099, India
| | - Punit H. Marathe
- Pharmaceutical
Candidate Optimization, Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Pennington, New Jersey 08534, United States
| | - Sandhya Mandlekar
- Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Bristol-Myers Squibb India Ltd., Bangalore 560099, India
| |
Collapse
|
2
|
Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds. Neurobiol Dis 2010; 37:38-47. [DOI: 10.1016/j.nbd.2009.09.025] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2009] [Revised: 09/29/2009] [Accepted: 09/30/2009] [Indexed: 11/24/2022] Open
|
3
|
Höcht C, Opezzo JAW, Taira CA. Hypothalamic Antihypertensive Effect of Irbesartan in Chronic Aortic Coarctated Rats. Pharmacology 2005; 73:146-54. [PMID: 15564789 DOI: 10.1159/000082348] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2004] [Accepted: 09/13/2004] [Indexed: 11/19/2022]
Abstract
The aim of the present work was to study the central and plasma pharmacokinetics of irbesartan (IRB) and its possible hypothalamic antihypertensive effect in sham-operated (SO) and aortic-coarctated (ACo) rats at a chronic hypertensive stage using the microdialysis technique. Anesthetized Wistar rats were used 42 days after ACo or SO. For the study of plasma pharmacokinetics, a vascular shunt probe was inserted into the carotid artery. In a separated experiment, a concentric probe was placed into the anterior hypothalamus for the study of IRB distribution in the central nervous system. Based on the hypothalamic concentrations of IRB reached in ACo rats, the anterior hypothalamus of SO and ACo animals was perfused with a Ringer solution containing approximately 6 microg x ml(-1) of the drug. IRB (10 mg x kg(-1) i.v.) induced a late decrease of heart rate (HR) in ACo animals (DeltaHR: -42 +/- 10 bpm, n = 5, p < 0.05 vs. SO rats) but not in SO rats (DeltaHR: 11 +/- 13 bpm, n = 5). Systemic administration of the drug reduced the mean arterial pressure (MAP) of both experimental groups, but the hypotensive effect was greater in ACo (DeltaMAP: -39.9 +/- 5.0 mm Hg, n = 5, p < 0.05 vs. SO rats) than in SO rats (DeltaMAP: -25.4 +/- 2.1 mm Hg, n = 5). A similar pharmacokinetic profile was observed in both experimental groups. Hypothalamic distribution of IRB was greater in ACo (AUC: 730 +/- 130 ng x ml(-1) h(-1), n = 5, p < 0.05 vs. SO rats) than in SO animals (AUC: 283 +/- 87 ng x ml(-1) h(-1), n = 5). The IRB hypothalamic perfusion induced an antihypertensive effect in ACo (DeltaMAP: -15.1 +/- 1.0 mm Hg, n = 5, p < 0.05 vs. Ringer perfusion) but not in SO rats. In conclusion, the chronic aortic coarctation did not modify the plasma pharmacokinetics of IRB, but it increased the distribution of the drug in the central nervous system. The greater hypotensive effect of IRB observed in ACo animals suggests the involvement of AT1 receptors in the maintenance of the hypertensive stage in chronic ACo rats. The hypotensive effect of IRB in ACo animals could be explained, at least in part, due an action on the anterior hypothalamic angiotensin system.
Collapse
Affiliation(s)
- Christian Höcht
- Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
| | | | | |
Collapse
|
4
|
Höcht C, Opezzo JAW, Taira CA. Pharmacokinetics and the Cardiovascular Effects of Irbesartan in Aortic Coarctated Rats. Pharmacology 2003; 70:23-30. [PMID: 14646353 DOI: 10.1159/000074239] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2003] [Accepted: 06/25/2003] [Indexed: 11/19/2022]
Abstract
A pharmacokinetic-pharmacodynamic study of irbesartan (IRB) was performed in anesthetized sham-operated (SO) and aortic coarctated (ACo) rats. Anesthetized Wistar rats were used 7 days after ACo procedure or SO. A vascular shunt probe was inserted into the carotid artery for the study of plasma pharmacokinetics. In a separate experiment, a concentric probe was placed into the anterior hypothalamus for the study of the IRB distribution in the central nervous system. IRB (10 mg.kg(-1) i.v.) induced a rapid decrease of the heart rate (HR) in the ACo animals (Delta HR -19.2 +/- 2.0 bpm, n = 6; p < 0.05 vs. basal HR), but not in the SO rats (Delta HR -6.7 +/- 5.1 bpm, n = 6). Moreover, IRB reduced the mean arterial blood pressure in the animals of both experimental groups, but the hypotensive effect lasted longer in ACo rats than in SO animals. Analysis of blood samples showed a lower constant of elimination of IRB in ACo rats (Ke 0.67 +/- 0.28 h(-1), n = 5; p < 0.05) than in SO rats (Ke 1.72 +/- 0.30 h(-1), n = 6). Also, a greater distribution of IRB in the anterior hypothalamus was seen in the ACo rats (area under the curve 32 +/- 4 ng.ml(-1).h(-1), n = 6; p < 0.05) than in the SO rats (area under the curve 12 +/- 1 ng.ml(-1).h(-1)). The protein binding of IRB was similar in both experimental groups (SO rats 7.1 +/- 1.2%, n = 6; ACo rats 7.7 +/- 1.5%, n = 6). In conclusion, ACo reduces the plasma elimination of IRB, increasing the distribution in the central nervous system. The longer hypotensive effect of IRB observed in ACo animals could be explained by the slowest elimination of the drug in ACo rats. On the other hand, the effect of IRB on the HR suggested that angiotensin II modulates this parameter in ACo animals at an early stage of hypertension.
Collapse
Affiliation(s)
- Christian Höcht
- Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
| | | | | |
Collapse
|
5
|
Höcht C, Opezzo JW, Taira C. Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. J Pharm Biomed Anal 2003; 31:1109-17. [PMID: 12667927 DOI: 10.1016/s0731-7085(02)00652-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The aim of our study was to compare pharmacokinetic parameters of a highly bound protein drug, irbesartan, obtained from microdialysis data (MD) of arterial blood and conventional blood samples (BS). A new vascular shunt microdialysis probe was inserted into the carotid artery and one femoral vein was cannulated for i.v. administration of irbesartan. Microdialysis samples were collected every 15 min. Blood samples were taken every 15 min. Levels of drug were measured by HPLC. Pharmacokinetic parameters were estimated using TOPFIT program. Corrected MD were compared with BS taken at same time to determine protein binding. The irbesartan protein binding did not change during the experiment. The estimated Ke from MD and BS were similar (MD: 1.8+/-0.3 h(-1), n=5; BS: 1.7+/-0.2 h(-1), n=5). After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS. In conclusion, these results show that our new probe inserted in the carotid artery provides accurate MD to estimate pharmacokinetic parameters of a highly bound protein drug like irbesartan. On the other hand, MD were also useful to the in vivo study of drug protein binding and saturation in protein binding.
Collapse
Affiliation(s)
- Christian Höcht
- Cátedra de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, (C1113AAD), Buenos Aires, Argentina.
| | | | | |
Collapse
|
6
|
Abstract
Quantitative microdialysis in the central nervous system (CNS) has recently provided evidence for the existence of transporters as they relate to the brain distribution of a variety of drugs. Support for the existence of drug transporters in the blood-brain barrier (or in the blood-CSF barrier) comes from investigations that have found: unbound drug concentrations in brain fluids that are lower than corresponding levels in plasma; saturability of transport clearances across the blood-brain barrier and; the regulation of transport by putative inhibitors. Additional confirmatory evidence for the existence of active transport or carrier-mediated processes has also been derived from models that relate observed drug levels in the CNS with those in plasma or blood. The conclusion that reduced drug levels in brain fluids generally indicate the existence of active efflux transport is questioned. In the case of relatively polar compounds with modest blood-brain barrier permeability, lower unbound concentrations in brain may be a consequence of dilution by turnover of brain fluids. This review summarizes recent reports (grouped by class of compounds) where investigators have used microdialysis to examine the distribution of therapeutic agents to the CNS, and have reached conclusions regarding the functional presence of drug transporters in the brain.
Collapse
Affiliation(s)
- R J Sawchuk
- Department of Pharmaceutics, College of Pharmacy, Weaver-Densford Hall, Room 9-143B, 308 Harvard Street S.E., University of Minnesota, Minneapolis, MN 55455, USA.
| | | |
Collapse
|
7
|
Abstract
One of the most challenging tasks in the development of protein pharmaceuticals is to deal with physical and chemical instabilities of proteins. Protein instability is one of the major reasons why protein pharmaceuticals are administered traditionally through injection rather than taken orally like most small chemical drugs. Protein pharmaceuticals usually have to be stored under cold conditions or freeze-dried to achieve an acceptable shelf life. To understand and maximize the stability of protein pharmaceuticals or any other usable proteins such as catalytic enzymes, many studies have been conducted, especially in the past two decades. These studies have covered many areas such as protein folding and unfolding/denaturation, mechanisms of chemical and physical instabilities of proteins, and various means of stabilizing proteins in aqueous or solid state and under various processing conditions such as freeze-thawing and drying. This article reviews these investigations and achievements in recent years and discusses the basic behavior of proteins, their instabilities, and stabilization in aqueous state in relation to the development of liquid protein pharmaceuticals.
Collapse
Affiliation(s)
- W Wang
- Biotechnology, Bayer Corporation, 800 Dwight Way, Berkeley, CA 94701, USA.
| |
Collapse
|
8
|
Gunaratna C, Kissinger PT. Investigation of stereoselective metabolism of amphetamine in rat liver microsomes by microdialysis and liquid chromatography with precolumn chiral derivatization. J Chromatogr A 1998; 828:95-103. [PMID: 9916299 DOI: 10.1016/s0021-9673(98)00822-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The utility of microdialysis as a quantitative sampling technique for in vitro drug metabolism studies was demonstrated by investigating the stereoselective metabolism of D-, L- and DL-amphetamine by the cytochrome P-450 enzymes. Microdialysates containing the isomers of amphetamine and its metabolite were derivatized with the fluorescent chiral derivatizing agent, (-)-fluorenylethyl chloroformate. The diastereoisomers were isocratically separated by liquid chromatography (LC) on a reversed-phase C18, 3-micron (100 x 3.2 mm) column. The intra- and inter-assay relative standard deviation (R.S.D.) was below 10%. Michaelis-Menten parameters, K(m) and Vmax were obtained for the formation of both D- and L-hydroxyamphetamine from D-, L- and DL-amphetamine in the concentration range of 10-350 microM.
Collapse
Affiliation(s)
- C Gunaratna
- Bioanalytical Systems Inc., West Lafayette, IN 47906, USA
| | | |
Collapse
|
9
|
Ofner B, Boukhabza A, Pacha W, Amsterdam CV, Wintersteiger R. Determination of SDZ ICM 567 in blood and muscle microdialysis samples by microbore liquid chromatography with ultraviolet and fluorescence detection. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1997; 700:191-200. [PMID: 9390729 DOI: 10.1016/s0378-4347(97)00247-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Fast, simple and accurate methods for the determination of SDZ ICM 567, the 7-methoxy derivative of tropisetron, in microdialysates have been developed. Sampling by microdialysis from freely moving rats in the portal and jugular vein offers a new technology for pharmacokinetic studies by direct and continuous measurement of unbound drug concentrations with time. SDZ ICM 567 can be identified in small sample volumes of dialysates on a microbore high-performance liquid chromatography column-switching system with ultraviolet detection. In addition, determination of SDZ ICM 567 by fluorimetric detection has been developed for muscle microdialysates from rats. [14C]SDZ ICM 567 was used as reference substance for the estimation of the amount of substance transferred through the dialysis membrane. The radioactive measurement (RA) gave the recovery information, whereas the liquid chromatographic method detected the sum of [14C]SDZ ICM 567 and dialyzed SDZ ICM 567.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Anti-Anxiety Agents/administration & dosage
- Anti-Anxiety Agents/analysis
- Anti-Anxiety Agents/blood
- Anti-Anxiety Agents/pharmacokinetics
- Bridged Bicyclo Compounds, Heterocyclic/administration & dosage
- Bridged Bicyclo Compounds, Heterocyclic/analysis
- Bridged Bicyclo Compounds, Heterocyclic/blood
- Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics
- Chromatography, Liquid
- Dialysis Solutions/analysis
- Indoles/administration & dosage
- Indoles/analysis
- Indoles/blood
- Indoles/pharmacokinetics
- Injections, Intravenous
- Male
- Microdialysis/methods
- Pectoralis Muscles/chemistry
- Rats
- Rats, Wistar
- Reproducibility of Results
- Sensitivity and Specificity
- Spectrometry, Fluorescence
- Spectrophotometry, Ultraviolet
- Veins
Collapse
Affiliation(s)
- B Ofner
- Institute of Pharmaceutical Chemistry, Graz, Austria
| | | | | | | | | |
Collapse
|
10
|
Van Amsterdam C, Lemaire M. Pharmacokinetic profile of SDZ EAA 494 in blood, brain and CSF using microdialysis. Eur J Pharm Sci 1997. [DOI: 10.1016/s0928-0987(97)00267-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Abstract
The objective of this review is to survey the recent literature regarding the various applications of microdialysis in pharmacokinetics. Microdialysis is a relatively new technique for sampling tissue extracellular fluid that is gaining popularity in pharmacokinetic and pharmacodynamic studies, both in experimental animals and humans. The first part of this review discusses various aspects of the technique with regard to its use in pharmacokinetic studies, such as: quantitation of the microdialysis probe relative recovery, interfacing the sampling technique with analytical instrumentation, and consideration of repeated procedures using the microdialysis probe. The remainder of the review is devoted to a survey of the recent literature concerning pharmacokinetic studies that apply the microdialysis sampling technique. While the majority of the pharmacokinetic studies that have utilized microdialysis have been done in the central nervous system, a growing number of applications are being found in a variety of peripheral tissue types, e.g. skin, muscle, adipose, eye, lung, liver, and blood, and these are considered as well. Given the rising interest in this technique, and the ongoing attempts to adapt it to pharmacokinetic studies, it is clear that microdialysis sampling will have an important place in studying drug disposition and metabolism.
Collapse
Affiliation(s)
- W F Elmquist
- Department of Pharmaceutical Sciences, College of Pharmacy University of Nebraska Medical Center, Omaha 68198, USA
| | | |
Collapse
|
12
|
Desrayaud S, Guntz P, Scherrmann JM, Lemaire M. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 1997; 61:153-63. [PMID: 9217274 DOI: 10.1016/s0024-3205(97)00370-6] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The effect of the multidrug resistance-reversing agent, SDZ PSC 833, on blood and brain pharmacokinetics of a P-glycoprotein substrate, colchicine, was investigated using simultaneous blood and brain microdialysis in freely moving rats. The use of microdialysis for pharmacokinetic studies was validated by comparing the blood concentrations of colchicine obtained by microdialysis with those obtained by direct blood sampling. The rats received either SDZ PSC 833 (2.3 mg/kg i.v. bolus followed by 16.7 microg/min/kg i.v. infusion during all the experiment) and colchicine (1 mg/kg i.v. bolus followed by 12.5 microg/min/kg i.v. infusion during 2 hours) or colchicine alone (the same dosage with SDZ PSC 833 vehicle). The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance. Moreover the coadministration of SDZ PSC 833 increased the brain penetration of colchicine by a factor of 10, at least. This enhancement could not be exactly assessed because the brain dialysate concentrations of control group were below the limit of detection. Nevertheless, the large increase of colchicine brain penetration is consistent with the hypothesis that SDZ PSC 833 is able to inhibit the P-glycoprotein pump present at the blood-brain barrier.
Collapse
Affiliation(s)
- S Desrayaud
- Drug Metabolism & Pharmacokinetics, Novartis Pharma Inc., Basel, Switzerland.
| | | | | | | |
Collapse
|
13
|
Olson RE, Christ DD. Chapter 33. Plasma Protein Binding of Drugs. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1996. [DOI: 10.1016/s0065-7743(08)60472-8] [Citation(s) in RCA: 195] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
14
|
Affiliation(s)
- W Wang
- Biotechnology Unit, Bayer Corp., Berkeley, CA 94701, USA
| |
Collapse
|
15
|
van Amsterdam C, Boukhabza A, Ofner B, Pacha W, Lemaire M. Measurement of free concentration of SDZ ICM 567 in blood and muscle using microdialysis sampling. Biopharm Drug Dispos 1995; 16:521-7. [PMID: 7579033 DOI: 10.1002/bdd.2510160609] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- C van Amsterdam
- Department of Drug Metabolism and Pharmacokinetics 507/801, Sandoz Pharma Ltd., Basel, Switzerland
| | | | | | | | | |
Collapse
|